Histone deacetylase inhibitor, suberoylanilide hydroxamic acid (SAHA), enhances anti-tumor effects of the poly (ADP-ribose) polymerase (PARP) inhibitor olaparib in triple-negative breast cancer cells.
about
Synergistic effects of combined treatment with histone deacetylase inhibitor suberoylanilide hydroxamic acid and TRAIL on human breast cancer cells.Identification of HRAS as cancer-promoting gene in gastric carcinoma cell aggressiveness.Crosstalk among the proteome, lysine phosphorylation, and acetylation in romidepsin-treated colon cancer cells.SAHA and/or MG132 reverse the aggressive phenotypes of glioma cells: An in vitro and vivo study.Deconvoluting the relationships between autophagy and metastasis for potential cancer therapy.Inhibiting sphingosine kinase 2 mitigates mutant Huntingtin-induced neurodegeneration in neuron models of Huntington disease.The multifaceted influence of histone deacetylases on DNA damage signalling and DNA repair.Enhanced efficacy of combined HDAC and PARP targeting in glioblastoma.Autophagy-related genes are induced by histone deacetylase inhibitor suberoylanilide hydroxamic acid via the activation of cathepsin B in human breast cancer cells.Histone Deacetylases as New Therapeutic Targets in Triple-negative Breast Cancer: Progress and PromisesScaffold dependent histone deacetylase (HDAC) inhibitor induced re-equilibration of the subcellular localization and post-translational modification state of class I HDACsTargeting triple negative breast cancer with histone deacetylase inhibitors.2-Phenylquinazolinones as dual-activity tankyrase-kinase inhibitors.Combined drug therapeutic strategies for the effective treatment of Triple Negative Breast Cancer.Targeting the Epigenome as a Novel Therapeutic Approach for Breast Cancer.Novel SAHA analogues inhibit HDACs, induce apoptosis and modulate the expression of microRNAs in hepatocellular carcinoma.Inhibition of histone deacetylases sensitizes glioblastoma cells to lomustine.The Epigenetics of Triple-Negative and Basal-Like Breast Cancer: Current KnowledgePARP inhibitor veliparib and HDAC inhibitor SAHA synergistically co-target the UHRF1/BRCA1 DNA damage repair complex in prostate cancer cellsInterplay of Histone Marks with Serine ADP-Ribosylation
P2860
Q36996317-F2C66D3F-DAA2-40A8-8249-729B93E9ABABQ37298284-71EABFB3-38E1-4C4C-A111-E6F151C8345EQ37619779-477CD1E1-4741-4CC9-B91C-A86B520529A4Q37709442-623578A8-E558-4D2C-A415-0A773C774932Q38784860-0D0B1923-B56C-481F-9073-B15A30EC28AAQ38973133-ABE04E10-5EDB-44C5-ADC2-92C71109D716Q38979892-A933BC26-DE95-4EFC-9F28-4F344C5B8B10Q40078610-B52E58C4-5CCC-4DAD-AF00-16C00AC79B6CQ41593165-3729B6A5-18D2-43FB-8A57-7F0C09886DC2Q41664067-B3148677-166A-4341-BDEA-849568264B17Q42680055-1F3278FB-30F0-4F27-B7BE-06176711C0C0Q47927498-AC534A89-8475-4697-9F63-772C48B0AEDFQ48158007-1442C5BC-8538-4952-B58D-1FBC9EEF3344Q48551091-82B1BF2C-4738-413A-B628-0C5B53DD145BQ49544302-873FCF65-3213-4734-A835-53B31A20572CQ51584555-836E80E6-BAB6-4C25-9C12-604049AD5E75Q51757810-46A4E16B-7EFF-4CF6-8BCC-612F31F932F8Q57107038-89955ABB-473B-40B6-9BDF-6F7962D5105FQ57175832-C9465F07-39DD-4656-B6AC-7111746CF8BFQ58697556-D72F8A99-C19B-420F-9834-46FBD6FEFD11
P2860
Histone deacetylase inhibitor, suberoylanilide hydroxamic acid (SAHA), enhances anti-tumor effects of the poly (ADP-ribose) polymerase (PARP) inhibitor olaparib in triple-negative breast cancer cells.
description
2015 nî lūn-bûn
@nan
2015年の論文
@ja
2015年論文
@yue
2015年論文
@zh-hant
2015年論文
@zh-hk
2015年論文
@zh-mo
2015年論文
@zh-tw
2015年论文
@wuu
2015年论文
@zh
2015年论文
@zh-cn
name
Histone deacetylase inhibitor, ...... -negative breast cancer cells.
@ast
Histone deacetylase inhibitor, ...... -negative breast cancer cells.
@en
type
label
Histone deacetylase inhibitor, ...... -negative breast cancer cells.
@ast
Histone deacetylase inhibitor, ...... -negative breast cancer cells.
@en
prefLabel
Histone deacetylase inhibitor, ...... -negative breast cancer cells.
@ast
Histone deacetylase inhibitor, ...... -negative breast cancer cells.
@en
P2093
P2860
P1476
Histone deacetylase inhibitor, ...... -negative breast cancer cells.
@en
P2093
Debora Keunyoung Kim
Do-Youn Oh
Hee-Jun Kim
Kyung-Hun Lee
Mark J O'Connor
Sae-Won Han
Sang-Hyun Song
Seock-Ah Im
Tae-Yong Kim
P2860
P2888
P356
10.1186/S13058-015-0534-Y
P577
2015-03-07T00:00:00Z
P5875
P6179
1037073692